Veterinary medicines European public assessment report (EPAR): CaniLeish, Leishmania infantum excreted secreted proteins, Date of authorisation: 14/03/2011, Revision: 2, Status: Withdrawn

Veterinary medicines European public assessment report (EPAR): CaniLeish, Leishmania infantum excreted secreted proteins, Date of authorisation: 14/03/2011, Revision: 2, Status: Withdrawn

Opinion/decision on a Paediatric investigation plan (PIP): cyanocobalamin,Diclofenac (potassium),pyridoxine (hydrochloride),Thiamine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0499/2022

Opinion/decision on a Paediatric investigation plan (PIP): cyanocobalamin,Diclofenac (potassium),pyridoxine (hydrochloride),Thiamine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0499/2022

Opinion/decision on a Paediatric investigation plan (PIP): Acetylsalicylic acid,rivaroxaban, decision type: , therapeutic area: , PIP number: P/0516/2022

Opinion/decision on a Paediatric investigation plan (PIP): Acetylsalicylic acid,rivaroxaban, decision type: , therapeutic area: , PIP number: P/0516/2022

Opinion/decision on a Paediatric investigation plan (PIP): eplerenone,Torasemide, decision type: , therapeutic area: , PIP number: P/0530/2022

Opinion/decision on a Paediatric investigation plan (PIP): eplerenone,Torasemide, decision type: , therapeutic area: , PIP number: P/0530/2022

Opinion/decision on a Paediatric investigation plan (PIP): Indapamide,valsartan, decision type: , therapeutic area: , PIP number: P/0547/2022

Opinion/decision on a Paediatric investigation plan (PIP): Indapamide,valsartan, decision type: , therapeutic area: , PIP number: P/0547/2022

Opinion/decision on a Paediatric investigation plan (PIP): 2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid, decision type: , therapeutic area: , PIP number: P/0482/2022

Opinion/decision on a Paediatric investigation plan (PIP): 2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid, decision type: , therapeutic area: , PIP number: P/0482/2022

Human medicines European public assessment report (EPAR): Prolia, denosumab, Bone Resorption;Osteoporosis, Postmenopausal, Date of authorisation: 26/05/2010, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Prolia, denosumab, Bone Resorption;Osteoporosis, Postmenopausal, Date of authorisation: 26/05/2010, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Heplisav B, hepatitis B surface antigen, Hepatitis B, Date of authorisation: 18/02/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Heplisav B, hepatitis B surface antigen, Hepatitis B, Date of authorisation: 18/02/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Brintellix, vortioxetine, Depressive Disorder, Major, Date of authorisation: 18/12/2013, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Brintellix, vortioxetine, Depressive Disorder, Major, Date of authorisation: 18/12/2013, Revision: 23, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.